Loading
A Californian company behind AccuScan, a whole-genome blood test for leftover cancer that corrects sequencing errors read by read.
AccuraGen Inc of San Jose, California, developed AccuScan with Shanghai YunSheng Medical Laboratory, according to the affiliations of the 2024 EMBO Molecular Medicine paper describing it. Its website could not be reached when this record was written.
A whole-genome blood test for leftover cancer from AccuraGen that corrects sequencing errors read by read, so it can add up thousands of a tumour's mutations.
Shares Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction, AccuScan, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/